Literature DB >> 22281834

Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.

Alex J Mackay1, Gavin C Donaldson, Anant R C Patel, Paul W Jones, John R Hurst, Jadwiga A Wedzicha.   

Abstract

RATIONALE: The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an eight-item questionnaire designed to assess and quantify the impact of COPD symptoms on health status. COPD exacerbations impair quality of life and are characterized by worsening respiratory symptoms from the stable state. We hypothesized that CAT scores at exacerbation relate to exacerbation severity as measured by exacerbation duration, lung function impairment, and systemic inflammation.
OBJECTIVES: To evaluate the usefulness of the CAT to assess exacerbation severity.
METHODS: One hundred sixty-one patients enrolled in the London COPD cohort completed the CAT at baseline (stable state), exacerbation, and during recovery between April 2010 and June 2011.
MEASUREMENTS AND MAIN RESULTS: Frequent exacerbators had significantly higher baseline CAT scores than infrequent exacerbators (19.5 ± 6.6 vs. 16.8 ± 8.0, P = 0.025). In 152 exacerbations, CAT scores rose from an average baseline value of 19.4 ± 6.8 to 24.1 ± 7.3 (P < 0.001) at exacerbation. Change in CAT score from baseline to exacerbation onset was significantly but weakly related to change in C-reactive protein (rho = 0.26, P = 0.008) but not to change in fibrinogen (rho = 0.09, P = 0.351) from baseline to exacerbation. At exacerbation, rises in CAT score were significantly associated with falls in FEV(1) (rho = -0.20, P = 0.032). Median recovery time as judged by symptom diary cards was significantly related to the time taken for the CAT score to return to baseline (rho = 0.42, P = 0.012).
CONCLUSIONS: The CAT provides a reliable score of exacerbation severity. Baseline CAT scores are elevated in frequent exacerbators. CAT scores increase at exacerbation and reflect severity as determined by lung function and exacerbation duration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22281834     DOI: 10.1164/rccm.201110-1843OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  76 in total

1.  Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much.

Authors:  Stephen I Rennard; Kristina L Bailey
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

Review 2.  Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Authors:  Sibel Atış Naycı; Lütfi Çöplü; Alev Gürgün; Nurdan Köktürk; Mehmet Polatlı; Elif Şen; Sema Umut; Esra Uzaslan; Nurhayat Yıldırım; Peter J Barnes
Journal:  Turk Thorac J       Date:  2015-04-01

3.  Comparison of face-to-face interview and telephone interview administration of COPD assessment test: a randomized study.

Authors:  Guilherme F da Silva; Maria Tereza A Morano; Maria Penha U Sales; Natalia B Olegário; Antonio George M Cavalcante; Eanes D B Pereira
Journal:  Qual Life Res       Date:  2013-11-01       Impact factor: 4.147

4.  Does the COPD assessment test (CAT(TM)) questionnaire produce similar results when self- or interviewer administered?

Authors:  A Agusti; J J Soler-Cataluña; J Molina; E Morejon; M Garcia-Losa; M Roset; X Badia
Journal:  Qual Life Res       Date:  2015-04-07       Impact factor: 4.147

5.  Obstructive Sleep Apnea in Patients With Fibrotic Interstitial Lung Disease and COPD.

Authors:  Xiao Lei Zhang; Hua Ping Dai; Hui Zhang; Bo Gao; Li Zhang; Teng Han; Chen Wang
Journal:  J Clin Sleep Med       Date:  2019-10-26       Impact factor: 4.062

6.  Correlation between decrease of CRP and resolution of airway inflammatory response, improvement of health status, and clinical outcomes during severe acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Ying Liang; Chun Chang; Hong Zhu; Ning Shen; Bei He; Wanzhen Yao
Journal:  Intern Emerg Med       Date:  2015-03-31       Impact factor: 3.397

7.  Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hana Müllerová; Mark T Dransfield; Byron Thomashow; Paul W Jones; Stephen Rennard; Niklas Karlsson; Malin Fageras; Norbert Metzdorf; Stefano Petruzzelli; Jean Rommes; Frank C Sciurba; Maggie Tabberer; Debora Merrill; Ruth Tal-Singer
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

8.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.

Authors:  MeiLan K Han; Hana Muellerova; Douglas Curran-Everett; Mark T Dransfield; George R Washko; Elizabeth A Regan; Russell P Bowler; Terri H Beaty; John E Hokanson; David A Lynch; Paul W Jones; Antonio Anzueto; Fernando J Martinez; James D Crapo; Edwin K Silverman; Barry J Make
Journal:  Lancet Respir Med       Date:  2012-09-03       Impact factor: 30.700

9.  Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value.

Authors:  Darwin Feliz-Rodriguez; Santiago Zudaire; Carlos Carpio; Elizabet Martínez; Antonia Gómez-Mendieta; Ana Santiago; Rodolfo Alvarez-Sala; Francisco García-Río
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

10.  Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial.

Authors:  Andrew I Ritchie; Simon E Brill; Ben H Vlies; Lydia J Finney; James P Allinson; Luana Alves-Moreira; Dexter J Wiseman; Paul P Walker; Emma Baker; Sarah L Elkin; Patrick Mallia; Martin Law; Gavin C Donaldson; Peter M A Calverley; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.